ADC Therapeutics appoints David Gilman as Chief Business & Strategy Officer
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Gilman will be responsible for all business development and portfolio strategy efforts globally.
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
Becomes the first airline globally to develop and launch sustainable, temperature-controlled containers for the transportation of pharmaceuticals
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
Thermo Scientific Direct Mass Technology mode augments Thermo Scientific Q Exactive UHMR Hybrid Quadrupole-Orbitrap mass spectrometers with charge detection capabilities
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Amarex Clinical Research guides its client to phase II of FDA trials
Subscribe To Our Newsletter & Stay Updated